Oral Presentations from Proffered Abstracts

Immunotherapy

PR-001  **Ex vivo co-culture system with patient-derived organoids to assess CXCR4 inhibitor as an immune modulating agent for human pancreas adenocarcinoma.** Emily Alouani1, Ilenia Pellicciotta1, Winston Wong1, Alexander S. Thomas2, Michael D. Kluger2, Anna M. Chiarella1, Anil K. Rustgi1, Gulum A. Manji1. 1Columbia University Irving Medical Center, New-York, NY, 2Columbia University, New York, NY.

Early Phase Clinical Trials

PR-002  **A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC).** Erkut Borazanci1, Gayle S. Jameson1, Sunil Sharma1, Frank Tsai2, Ronald L. Korn3, Lana Caldwell2, Karen Ansal02, David T. Ting4, Denise Roe5, Anna Bermudez2, Daniel D. Von Hoff1. 1HonorHealth/TGen, Scottsdale, AZ, 2HonorHealth, Scottsdale, AZ, 3Imaging Endpoints, Scottsdale, AZ, 4Massachusetts General, Boston, MA, 5University of Arizona, Tucson, AZ.

Immunotherapy

PR-003  **High quality neoantigens are immunoedited in long-term pancreatic cancer survivors.** Luis A. Rojas1, Marta Łuksza2, Zachary M. Sethna1, Kevin Soares1, Joanne Leung1, Jayon Lihm1, David Hoyos1, Anton Dobrin1, Rajya Kappagantula1, Alvin Makohon-Moore1, Amber Johns3, Anthony Gill3, Masataka Amisaki1, Pablo Guasp1, Abderezak Zebboudj1, Rebecca Yu1, Adrienne Kaya Chandra1, Zagaa Odgerel1, Michel Sadelain1, Erin Patterson1, Christine Iacobuzio-Donahue1, Benjamin D Greenbaum1, Vinod P. Balachandran1. 1Memorial Sloan Kettering Cancer Center, New York, NY, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Garvan Institute of Medical Research, New South Wales, Australia.

PR-004  **Inhibition of focal adhesion kinase (FAK) improves pancreatic ductal adenocarcinoma’s response to immunotherapy by targeting cancer stem cells (CSCs).** Yezi Zhu1, Lyndsey Sandow2, William Matsui1. 1LIVESTRONG Cancer Institute, Dell Medical School, UT Austin, Austin, TX, 2Oregon Health & Science University, Portland, OR.

Big Data

PR-005  **Chromatin dynamics in vivo define coordinate functions of inflammation and mutant Kras in pancreatic tumorigenesis.** David Falvo1, Jason Pitaresi2, Alexa Osterhoudt1, Adrien Grimont1, Ben Stanger2, Steven D. Leach3, Anil K. Rustgi4, Rohit Chandwani1. 1Weill Cornell Medicine, New York, NY, 2University of Pittsburgh, Philadelphia, PA, 3Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 4Columbia University Irving Medical Center, New York, NY.

PR-006  **Integrative genomic characterization of therapeutic targets for pancreatic...**
cancer. Jimmy A. Guo\textsuperscript{1}, Daniel Zhao\textsuperscript{2}, Scott P. Ginebaugh\textsuperscript{3}, Steven Wang\textsuperscript{4}, Ananya D. Jambhale\textsuperscript{1}, Patrick Z. Yu\textsuperscript{1}, Westley W. Wu\textsuperscript{1}, Peter Chen\textsuperscript{1}, Maryann Zhao\textsuperscript{1}, Kristen E. Lowder\textsuperscript{3}, Kevin S. Kapner\textsuperscript{3}, Hannah I. Hoffman\textsuperscript{1}, Stephanie W. Cheng\textsuperscript{5}, Daniel Y. Kim\textsuperscript{6}, Rebecca Boiarsky\textsuperscript{7}, Francois Aguet\textsuperscript{1}, Brenton Paolella\textsuperscript{1}, John M. Krill-Burger\textsuperscript{1}, James M. McFarland\textsuperscript{1}, Tobiloba Oni\textsuperscript{8}, Tyler Jacks\textsuperscript{7}, Aviv Regev\textsuperscript{9}, Gad Getz\textsuperscript{1}, William L. Hwang\textsuperscript{10}, Harshabad Singh\textsuperscript{3}, Andrew J. Aguirre\textsuperscript{3}. 1Broad Institute of MIT and Harvard, Cambridge, MA, 2New York Medical College, Valhalla, NY, 3Dana Farber Cancer Institute, Boston, MA, 4Columbia University, New York, NY, 5Stanford University, Palo Alto, CA, 6Harvard Medical School, Boston, MA, 7MIT, Cambridge, MA, 8Whitehead Institute, Cambridge, MA, 9Genentech, San Francisco, CA, 10Massachusetts General Hospital, Boston, MA.

**PR-007** Lung-tropic, liver-averse, primary PDAC tumors are associated with greater peripheral T cell diversity and have a unique, subtype-independent, gene-expression signature that significantly correlates with longer survival. Jason M. Link, Patrick J. Worth, Dove Keith, Sydney Owen, Alison Grossblatt-Wait, Carl Pelz, Hannah Holly, Motoyuki Tsuda, Kevin MacPherson, Jonathan Brody, Charles Lopez, Brett C. Sheppard, Rosalie C. Sears. 1Oregon Health & Science University, Portland, OR.

**Signaling**

**PR-008** Kdm6 demethylases are critical regulators of pancreatic cancer initiation, progression and subtype specification. Laura Leonhardt, Lucia Y. Li, David I. Berrios, Sudipta Ashe, Audrey M. Hendley, Grace E. Kim, Matthias Hebrok. University of California San Francisco, San Francisco, CA.

**Metabolism**

**PR-009** Targeting the sterol regulatory element-binding protein pathway in pancreatic ductal adenocarcinoma. Stephanie Myers, Meredith McGuire, Wei Shao, Chine Liu, Theodore Ewachiw, Zeshaan Rasheed, William Matsui, Toni Sepalla, Richard Burkhart, Peter Espenshade. Johns Hopkins University, School of Medicine, Baltimore, MD.

**Signaling**

**PR-010** Collateral amplification of the KRAS linked gene PTHLH governs pancreatic cancer growth and metastasis and reveals a new therapeutic vulnerability. Jason R. Pitarresi\textsuperscript{1}, Robert J Norgard\textsuperscript{1}, Anna M. Chiarella\textsuperscript{2}, Kensuke Suzuki\textsuperscript{2}, Richard Kremer\textsuperscript{3}, Ben Z. Stanger\textsuperscript{1}, Anil K. Rustgi\textsuperscript{2}. 1University of Pennsylvania, Philadelphia, PA, 2Columbia University, New York City, NY, 3McGill University, Montreal, QC, Canada.

Tumor Microenvironment

PR-012  Targeting the Wnt-YAP crosstalk as a therapeutic approach to treat pancreatic cancer. Bekesho Geleta, Zaklina Kovacevic, 1Children's Cancer Institute Australia, Sydney, NSW, Australia, 2University of Sydney, Sydney, NSW, Australia.

PR-013  The splanchnic mesenchyme during fetal development is the major source of pancreatic cancer associated fibroblasts. Lu Han, Yongxia Wu, Melodie Parrish, Khushbu Patel, Xuezhong Yu, Michael Ostrowski, Gustavo Leone. 1Medical University of South Carolina, Charleston, SC, 2Medical College of Wisconsin, Milwaukee.

PR-014  Hedgehog represses angiogenesis in PDAC through a paracrine cascade mediated by Wif1. Marie C. Hasselluhn, Amanda R. Decker, Alvaro Curiel Garcia, Carlo Maurer, Dafydd Thomas, Kenneth P. Olive. 1Columbia University Irving Medical Center, New York, NY, 2Technische Universität München, Munich, Germany, 3PMV Pharmaceuticals, Inc., Cranbury, NJ.

PR-015  Cancer-associated fibroblasts sustain critical dependency of pancreatic cancer cells on exogenous lipids. Charline Ogier, Alena Klochkova, Linara Gabitova, Battuya Bayarmagnai, Diana Restifo, Aizhan Surumbayeva, Janusz Franco-Barrasa, Ralph Francescone, Debora B. Barbosa Vendramini-Costa, Jaye Gardiner, Emmanuelle Nicolas, Elizabeth A. Handorf, KATHY Q. CAI, Edna Cukierman, Igor Astsaturov. 1The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, 2Temple University Lewis Katz School of Medicine, Philadelphia, PA, 3Department of Bioengineering, Temple University, Philadelphia, PA, 4Genomic Facility, Fox Chase Cancer Center, Philadelphia, PA, 5Biostatistic Facility, Fox Chase Cancer Center, Philadelphia, PA, 6Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA.